Page 12 of 26

PE18.5 | Immunization in Special Situations — SDL Guide (Part 2)

Immunization in Preterm and Low Birth Weight Infants

Preterm and low birth weight (LBW) infants present a common special situation in Indian paediatric practice, given the high rates of preterm birth. The governing principle for most vaccines is straightforward and important to state precisely: vaccinate at chronological age (date of birth), not corrected gestational age. This means a preterm infant born at 28 weeks gestation who reaches 6 weeks chronological age receives the 6-week NIS vaccines at that time, regardless of the fact that the infant is only 34 weeks post-conception. Studies demonstrate equivalent immunogenicity of NIS vaccines at chronological versus corrected gestational age; delaying vaccination by correcting for prematurity leaves the infant unprotected at the age of maximum vulnerability.

Full doses of all vaccines are given at the standard chronological age, with two important exceptions:

BCG in low birth weight infants: BCG is deferred if birth weight is less than 2 kg. This is because the local BCG reaction and lymphadenitis in very small infants can be disproportionately severe, and the immune response may be suboptimal at very low birth weight. The practical rule: give BCG at discharge from NICU/nursery when weight has reached ≥2 kg, or at 6 weeks chronological age if the infant has not yet reached 2 kg by discharge (give regardless at 6 weeks).

Hepatitis B in infants of HBsAg-positive mothers: The hepatitis B birth dose must be given within 24 hours of birth regardless of gestational age or birth weight. The risk of perinatal transmission from an HBsAg-positive mother, and the risk of chronic hepatitis B infection if transmission occurs neonatally (~90% chronicity rate), outweighs any theoretical concern about preterm immune response. This is an absolute priority: even a 25-week preterm infant born to a hepatitis B carrier mother should receive HepB birth dose within 24 hours, along with hepatitis B immunoglobulin (HBIG) if available.

Rotavirus vaccine is given at 6 weeks (or the first post-discharge visit after 6 weeks), with the same first-dose age cut-off of 15 weeks — prematurity does not extend this window. The final dose of rotavirus must be completed by 32 weeks (IAP). Preterm infants do not have a differential risk of intussusception from rotavirus vaccination compared to term infants.

The hepatitis B primary series (via pentavalent) is started at 6 weeks as standard. The birth dose of HepB in preterm infants born to HBsAg-negative mothers may be counted as dose 1 of the primary series regardless of gestational age, completing the 3-dose series at 6/10/14 weeks via pentavalent. For very preterm infants, some programmes delay counting the birth dose and restart the series at 6 weeks — the final schedule depends on local guidance, but the total number of doses and the intervals between them are the same.

Immunization after Blood and Blood Products; Asplenia; Adolescents; Travellers

These four situations — passive antibody interference from blood products, impaired splenic clearance in asplenia, adolescent catch-up, and travel-specific pathogens — each require a distinct modification to the standard immunization approach. Although these situations are grouped here for convenience, they are epidemiologically common and will be encountered in any general paediatric or community medicine practice in India. Passive antibody interference from blood products is particularly relevant in Indian hospitals where blood transfusions for anaemia, haemolytic disease, and sickle cell crises are frequent; asplenia is encountered in sickle cell disease, hereditary spherocytosis, and trauma; and international travel for Hajj/Umrah pilgrimage or work migration means travel vaccines are a routine primary-care concern even outside metropolitan cities.

After blood and blood products:
Passive antibodies in transfused blood, immunoglobulin (IVIG), or plasma can interfere with the immune response to live attenuated vaccines — specifically MR and varicella — by neutralising the attenuated virus before an adequate immune response can develop. Non-live vaccines are unaffected. The minimum deferral intervals for live vaccines after blood products are:

Blood Product	Minimum Deferral Interval Before Live Vaccine
Washed red blood cells	3 months
Packed red blood cells (PRBC)	6 months
Whole blood	6 months
IVIG (low dose, ≤80 mg/kg)	3 months
IVIG (high dose, 1–2 g/kg)	10–11 months
Specific immunoglobulin (e.g., tetanus IG)	3 months

If a live vaccine (MR) was given less than 2 weeks before a blood product, the vaccine should be repeated after the appropriate deferral interval.

Asplenia (functional or surgical):
The spleen is critical for clearing encapsulated bacteria (pneumococci, Haemophilus influenzae, meningococci, salmonella) and IgM opsonisation. Children with asplenia (sickle cell disease causes functional asplenia; splenectomy is performed for haematological conditions and trauma) have dramatically increased susceptibility to overwhelming post-splenectomy infection (OPSI) — a rapidly fatal bacterial sepsis. Key vaccines:
• PCV and pneumococcal polysaccharide vaccine (PPSV23) — if not already received, give as priority.
• Hib conjugate — if not received as part of primary series.
• Meningococcal conjugate vaccine (MenACWY) — particularly for Indian children with asplenia or in Hajj/Umrah travellers.
• Influenza — annual inactivated influenza vaccine.
• For elective splenectomy: give all recommended vaccines at least 2 weeks before the procedure. For emergency splenectomy: give as soon as haematologically stable (typically 2–4 weeks post-surgery).
• Penicillin prophylaxis (amoxicillin or phenoxymethylpenicillin) is given as adjunct to vaccines — but vaccines are not replaced by prophylaxis.

Adolescents:
Catch-up immunization for adolescents who missed childhood vaccines follows the same principle as any catch-up — continue from where the series was interrupted, respect minimum intervals. Priority vaccines for adolescents: TT/Td booster (at 10 and 16 years under NIS), HPV vaccine (especially girls, ideally before sexual debut; 3-dose schedule for ≥15 years), annual influenza for high-risk adolescents, HepA and TCV if not previously received. MR-2 catch-up if second dose was missed.

Travellers:
Children travelling to areas endemic for specific infections require additional vaccines beyond the NIS:
• Japanese Encephalitis: For travel to/from endemic districts in India; also for international travel to South/Southeast Asia.
• Hepatitis A: Recommended for all travellers to endemic areas (most of South Asia); 2 doses.
• Typhoid Conjugate Vaccine (TCV): Strongly recommended for South Asian travellers; also indicated for Indian children regardless of travel.
• Meningococcal vaccine: Mandatory for Hajj/Umrah (Saudi Arabia requires MenACWY certificate); recommended for travel to the 'meningitis belt' of Sub-Saharan Africa.
• Yellow fever: Required certificate for entry into/from yellow fever endemic countries; only available at designated centres in India.
• Cholera oral vaccine: Not routinely recommended; for specific humanitarian/endemic situations.

Applied Principles: A Decision Framework for Special Situations

Rather than memorising lists for every special situation, internalising a decision framework is more clinically durable and more generalisable to situations not explicitly covered in any table. The framework has five steps that can be applied at the bedside or in the OPD to any child presenting in a special situation for immunization.

Step 1 — Identify the special situation. Is this an immunocompromised child (HIV, PID, chemotherapy, transplant, high-dose steroids)? A preterm/LBW infant? A child who recently received blood products? A child with asplenia? An adolescent needing catch-up? A child travelling internationally? One child may have more than one special situation (e.g., a preterm infant on NICU who received multiple blood transfusions).

Step 2 — For each due vaccine, classify as LIVE or NON-LIVE. This classification determines the risk in immunocompromised patients. Non-live vaccines almost universally proceed; live vaccines require Step 3.

Step 3 — Assess the degree and reversibility of immunosuppression. In HIV: CD4 percentage. In steroid use: dose and duration (≥2 mg/kg/day for ≥2 weeks = defer live vaccines until ≥1 month post-treatment). In chemotherapy: active treatment vs completed ≥3–6 months ago. In transplant: on immunosuppression vs ≥2 years post-transplant with stable immunosuppression. Mild/moderate immunosuppression often permits live vaccines; severe immunosuppression does not.

Step 4 — Decide: proceed / defer / substitute / omit.
• Proceed: Non-live vaccine in any immunocompromised patient; live vaccine in adequately immune patient.
• Defer: Live vaccine in transiently immunosuppressed patient — note expected date of recovery and reschedule.
• Substitute: OPV → IPV in any immunocompromised patient or their household contacts; live JE → inactivated JE for severely immunocompromised travellers.
• Omit: Live vaccine in SCID or permanent severe PID (will never be safe to give).

Step 5 — Document and communicate. Record the special situation in the immunization card, the vaccines given and deferred, and the planned catch-up schedule. Communicate the plan clearly to parents. For complex cases (transplant, PID), liaise with the specialist managing the underlying condition.

This five-step approach is the practical expression of Principle 3 (defer, not omit), Principle 4 (household contacts), and the non-live-vaccines-always-proceed rule.